Jun Liu MM , Xiaochun Chen BS , Lei Xu MM , Fan Tu BS , Xiaohong Rui BS , Lizhu Zhang MM , Zhihan Yan BS , Yun Liu MM , Renjing Hu BS
{"title":"中性粒细胞膜包被纳米颗粒在抗微生物耐药肺炎克雷伯菌感染模型中表现出增强的抗菌活性","authors":"Jun Liu MM , Xiaochun Chen BS , Lei Xu MM , Fan Tu BS , Xiaohong Rui BS , Lizhu Zhang MM , Zhihan Yan BS , Yun Liu MM , Renjing Hu BS","doi":"10.1016/j.nano.2022.102640","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p><span>To investigate the efficacy and safety of neutrophil<span><span><span> membrane-coated nanoparticles mediated KLA peptides (KLAKLAKKLAKLAK) and </span>gentamicin in the </span>targeted therapy of anti-microbial resistant </span></span><span><em>Klebsiella </em><em>pneumoniae</em></span> (<em>K. pneumonia</em>) lung infection.</p></div><div><h3>Methods</h3><p>The characteristics of KLA-neutrophils nanoparticles (NNPs) are identified <em>via</em><span><span><span> dynamic light scattering (DLS), transmission </span>electron microscope<span> (TEM), SDS-PAGE, Western blot, quantitative flow cytometry (QFCM) and </span></span>confocal microscopy. The safety of KLA-NNPs both </span><em>in vitro</em> and <em>in vivo</em><span><span><span> is evaluated by hemolysis test, platelet α granule </span>membrane protein concentration, protein </span>adsorption capacity, </span><em>in vitro</em><span> macrophage phagocytosis<span><span>, weight change<span>, liver function indicators, blood biochemical indicators, and pathological changes of vital organs in mice. The efficacy of KLA-NNPs is determined by time-kill assay, </span></span>fluorescent label test, intracellular bacterial content, caspase-1 activity, survival rate, and HE staining both </span></span><em>in vitro</em> and <em>in vivo</em>.</p></div><div><h3>Results</h3><p><span>The prepared KLA-NNPs have a typical “core-shell” structure, uniform nanometer size, and retain the membrane proteins on the neutrophil membrane that achieve functional effects. </span><em>In vitro</em> safety analysis showed that KLA-NNPs have good blood compatibility and can inhibit macrophage phagocytosis <em>in vitro</em><span>. KLA-NNPs can effectively release KLA and significantly reduce intracellular bacteria and caspase-1 activity. </span><em>In vivo</em><span> safety analysis and efficacy analysis revealed that KLA-NNPs have good biocompatibility and could effectively improve the survival rate of mice.</span></p></div><div><h3>Conclusion</h3><p><span>The prepared KLA-NNPs have good nano-medicine chemical and physical properties and safety. It can evade immune system clearance, achieve high-efficiency targeted aggregation and drug delivery to bacterial infection sites, and effectively inhibit the development of pneumonia induced by drug-resistant </span><em>K. pneumonia</em>.</p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":"48 ","pages":"Article 102640"},"PeriodicalIF":4.7000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Neutrophil membrane-coated nanoparticles exhibit increased antimicrobial activities in an anti-microbial resistant K. pneumonia infection model\",\"authors\":\"Jun Liu MM , Xiaochun Chen BS , Lei Xu MM , Fan Tu BS , Xiaohong Rui BS , Lizhu Zhang MM , Zhihan Yan BS , Yun Liu MM , Renjing Hu BS\",\"doi\":\"10.1016/j.nano.2022.102640\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p><span>To investigate the efficacy and safety of neutrophil<span><span><span> membrane-coated nanoparticles mediated KLA peptides (KLAKLAKKLAKLAK) and </span>gentamicin in the </span>targeted therapy of anti-microbial resistant </span></span><span><em>Klebsiella </em><em>pneumoniae</em></span> (<em>K. pneumonia</em>) lung infection.</p></div><div><h3>Methods</h3><p>The characteristics of KLA-neutrophils nanoparticles (NNPs) are identified <em>via</em><span><span><span> dynamic light scattering (DLS), transmission </span>electron microscope<span> (TEM), SDS-PAGE, Western blot, quantitative flow cytometry (QFCM) and </span></span>confocal microscopy. The safety of KLA-NNPs both </span><em>in vitro</em> and <em>in vivo</em><span><span><span> is evaluated by hemolysis test, platelet α granule </span>membrane protein concentration, protein </span>adsorption capacity, </span><em>in vitro</em><span> macrophage phagocytosis<span><span>, weight change<span>, liver function indicators, blood biochemical indicators, and pathological changes of vital organs in mice. The efficacy of KLA-NNPs is determined by time-kill assay, </span></span>fluorescent label test, intracellular bacterial content, caspase-1 activity, survival rate, and HE staining both </span></span><em>in vitro</em> and <em>in vivo</em>.</p></div><div><h3>Results</h3><p><span>The prepared KLA-NNPs have a typical “core-shell” structure, uniform nanometer size, and retain the membrane proteins on the neutrophil membrane that achieve functional effects. </span><em>In vitro</em> safety analysis showed that KLA-NNPs have good blood compatibility and can inhibit macrophage phagocytosis <em>in vitro</em><span>. KLA-NNPs can effectively release KLA and significantly reduce intracellular bacteria and caspase-1 activity. </span><em>In vivo</em><span> safety analysis and efficacy analysis revealed that KLA-NNPs have good biocompatibility and could effectively improve the survival rate of mice.</span></p></div><div><h3>Conclusion</h3><p><span>The prepared KLA-NNPs have good nano-medicine chemical and physical properties and safety. It can evade immune system clearance, achieve high-efficiency targeted aggregation and drug delivery to bacterial infection sites, and effectively inhibit the development of pneumonia induced by drug-resistant </span><em>K. pneumonia</em>.</p></div>\",\"PeriodicalId\":396,\"journal\":{\"name\":\"Nanomedicine: Nanotechnology, Biology and Medicine\",\"volume\":\"48 \",\"pages\":\"Article 102640\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanomedicine: Nanotechnology, Biology and Medicine\",\"FirstCategoryId\":\"1\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1549963422001265\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine: Nanotechnology, Biology and Medicine","FirstCategoryId":"1","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1549963422001265","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Neutrophil membrane-coated nanoparticles exhibit increased antimicrobial activities in an anti-microbial resistant K. pneumonia infection model
Objective
To investigate the efficacy and safety of neutrophil membrane-coated nanoparticles mediated KLA peptides (KLAKLAKKLAKLAK) and gentamicin in the targeted therapy of anti-microbial resistant Klebsiella pneumoniae (K. pneumonia) lung infection.
Methods
The characteristics of KLA-neutrophils nanoparticles (NNPs) are identified via dynamic light scattering (DLS), transmission electron microscope (TEM), SDS-PAGE, Western blot, quantitative flow cytometry (QFCM) and confocal microscopy. The safety of KLA-NNPs both in vitro and in vivo is evaluated by hemolysis test, platelet α granule membrane protein concentration, protein adsorption capacity, in vitro macrophage phagocytosis, weight change, liver function indicators, blood biochemical indicators, and pathological changes of vital organs in mice. The efficacy of KLA-NNPs is determined by time-kill assay, fluorescent label test, intracellular bacterial content, caspase-1 activity, survival rate, and HE staining both in vitro and in vivo.
Results
The prepared KLA-NNPs have a typical “core-shell” structure, uniform nanometer size, and retain the membrane proteins on the neutrophil membrane that achieve functional effects. In vitro safety analysis showed that KLA-NNPs have good blood compatibility and can inhibit macrophage phagocytosis in vitro. KLA-NNPs can effectively release KLA and significantly reduce intracellular bacteria and caspase-1 activity. In vivo safety analysis and efficacy analysis revealed that KLA-NNPs have good biocompatibility and could effectively improve the survival rate of mice.
Conclusion
The prepared KLA-NNPs have good nano-medicine chemical and physical properties and safety. It can evade immune system clearance, achieve high-efficiency targeted aggregation and drug delivery to bacterial infection sites, and effectively inhibit the development of pneumonia induced by drug-resistant K. pneumonia.
期刊介绍:
Nanomedicine: Nanotechnology, Biology and Medicine (NBM) is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.